∙ Patients V.1.1. Diseases

∙ Hematological malignancies confirmed histologically:

• AML in morphological CR or not in morphological CR but not rapidly progressing (i.e. no need to give treatments such as hydroxyurea to maintain WBC count \< 10 000 x109/mL);

• MDS;

• CML in CP or AP;

• MPD not in blast crisis,

• MDS/MPD overlap,

• ALL in CR;

• Multiple myeloma;

• CLL;

• Non-Hodgkin's lymphoma (aggressive NHL should have chemosensitive disease);

• Hodgkin's disease with chemosensitive disease or responding to checkpoint inhibitors.

• \* Clinical situations

• • Theoretical indication for a standard allo-transplant, but not feasible because:

• Age \> 50 yrs;

• Unacceptable end organ performance;

• The physician's decision;

• The patient's decision

‣ Underlying 'lower risk' disease, for which Reduced Intensity Conditioning is preferred (eg CLL, MCL)

‣ \* Other inclusion criteria

⁃ Male or female; fertile patients must use a reliable contraception method;

⁃ Age 18-75 yrs (children of any age are not allowed in the protocol);

⁃ Informed consent given by patient or his/her guardian if indicated.

∙ Donors

• Male or female;

• Any age;

• Human Leukocyte Antigen (HLA)-identical sibling donor or 10 of 10 (HLA-A, -B, -C, -DRB1, and -DQB1) HLA allele matched unrelated donor;

• Weight \> 15 Kg (because of leukapheresis);

• Fulfills criteria for allogeneic Peripheral Blood Stem Cell (PBSC) donation according to standard procedures;

• Informed consent given by donor or his/her guardian if indicated, as per donor center standard procedures.